Advertisement

Adenosine Injection

[08 September 2014]

Products Affected - Description

No presentations on shortage.

Use in Paroxysmal Supraventricular Tachycardia
Adenosine Injection, 3 mg/mL, Akorn
2 mL vial, 10 count (NDC 17478-0542-02)

Adenosine Injection, 3 mg/mL, Ben Venue (formerly Bedford product)
2 mL vial, 10 count (NDC 55390-0067-10)
4 mL vial, 1 count (NDC 55390-0068-01)
 
Adenosine Injection, 3 mg/mL, Sagent
2 mL vial, 10 count (NDC 25021-0301-02)
2 mL prefilled syringe, 10 count (NDC 25021-0301-67)
4 mL vial, 10 count (NDC 25021-0301-04)
 
Adenosine Injection, 3 mg/mL, West-Ward
2 mL vial, 10 count (NDC 00641-6113-10)

Reason for the Shortage

  • Akorn launched adenosine 3 mg/mL 2 mL vials 25 count in April 2013.
  • Astellas had Adenoscan on back order due to increased demand. This back order is now resolved. Adenoscan is used for diagnostic purposes as an adjunct to thallium-201 myocardial perfusion scintigraphy. Adenocard and generic adenosine products are labeled for use in paroxysmal supraventricular tachycardia.
  • Ben Venue has stopped production in its plant in Bedford, Ohio and closed in July 2014.
  • Sagent has adenosine vials on shortage due to manufacturing delay.
  • Teva has discontinued their adenosine injection.
  • Wockhardt discontinued their adenosine 3 mg/mL 2 mL and 4 mL syringes.

Available Products

Diagnostic Adjunct
Adenoscan Injection, 3 mg/mL, Astellas
30 mL vial (NDC 00469-0871-30)
20 mL vial (NDC 00469-0871-20)

Use in Paroxysmal Supraventricular Tachycardia
Adenosine Injection, 3 mg/mL, Akorn
2 mL vial, 25 count (NDC 17478-0542-25)

Adenosine Injection, 3 mg/mL, Fresenius Kabi
2 mL vial, 10 count (NDC 63323-0651-02)
4 mL vial, 10 count (NDC 63323-0651-04)

Adenosine Injection, 3 mg/mL, Sagent
4 mL prefilled syringe (10 count, NDC 25021-0301-68)

Adenocard Injection, 3 mg/mL, Astellas
2 mL prefilled syringe (NDC 00469-8234-12)
4 mL prefilled syringe (NDC 00469-8234-14)

Estimated Resupply Dates

Diagnostic Adjunct
  •  Astellas has Adenoscan 3 mg/mL 20 mL and 40 mL vials available.
Use in Paroxysmal Supraventricular Tachycardia
  • Akorn has adenosine 2 mL vials on back order and the company estimates a release date in mid-September 2014.
  • Ben Venue has adenosine 2 mL and 4 mL vials on back order and the company cannot estimate a release date.
  • Sagent has adenosine 2 mL and 4 mL vials on back order and the company cannot estimate a release date. Adenosine 2 mL syringes are on back order and the company estimates a release date in late-September 2014.
  • West-Ward has adenosine 3 mg/mL 2 mL vials on back order and the company cannot estimate a release date.

Related Shortages

Updated

September 8, 2014; August 4, 2014; July 18, 2014; July 3, 2014; May 22, 2014; May 15, 2014; May 13, 2014; April 25, 2014; April 24, 2014; April 1, 2014; March 27, 2014; March 17, 2014; March 14, 2014; March 4, 2014; February 21, 2014; February 12, 2014; January 14, 2014; December 11, 2013; October 18, 2013; September 16, 2013; August 29, 2013; August 15, 2013; July 18, 2013; June 18, 2013; May 15, 2013; May 13, 2013; April 11, 2013; March 13, 2013; March 1, 2013; February 13, 2013; January 25, 2013; December 28, 2012; December 21, 2012; November 19, 2012, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement